🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Lisa G. Horvath

The University of Sydney

ORCID: 0000-0001-6842-9223

Also affiliated with Garvan Institute of Medical Research, Chris O’Brien Lifehouse, The Kinghorn Cancer Centre

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial”.

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(21)00757-9
N/A
4.9DataRank · unranked
188 citations

Howard I Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N Lara, Evan Y Yu +90 more

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

Nature Genetics(2021)10.1038/s41588-020-00748-0
N/A
0.934DataRank · unranked
504 citations

Burcu F. Darst, Lilit C. Moss, Edward J. Saunders, Xin Sheng, Alisha Chou +95 more

Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

Nature Genetics(2023)10.1038/s41588-023-01534-4
N/A
0.753DataRank · unranked
150 citations

Jiayi Shen, Alex A Rodriguez, Edward J. Saunders, Fei Chen, Rohini Janivara +95 more

Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial

Nature Medicine(2025)10.1038/s41591-025-03579-w
N/A
0.691DataRank · unranked
99 citations

Yuxuan Wang, Serigne Lo, Kamel Lahouel, Joshua D. Cohen, Rachel Wong +24 more

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype

EBioMedicine(2023)10.1016/j.ebiom.2023.104738
N/A
0DataRank · unranked
42 citations

Chao Dai, Edmond M. Kwan, Tiantian Zheng, Pan Du, Nicole Ng +12 more

Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance

Journal of Clinical Investigation(2024)10.1172/jci183583
N/A
0DataRank · unranked
7 citations

Robert Diaz, Hui‐Ming Lin, Evan Roberts, Lisa G. Horvath, Andrew Martin +7 more

318MO Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC)

Annals of Oncology(2022)10.1016/j.annonc.2022.07.456
N/A
0DataRank · unranked
14 citations

Jesse Cohen, Kamel Lahouel, Serigne Lo, Y. Wang, Rachel Wong +15 more

Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer

Prostate Cancer and Prostatic Diseases(2021)10.1038/s41391-021-00338-z
N/A
0DataRank · unranked
32 citations

Kevin Huynh, Manish Kohli, Winston Tan, Arun Azad, Nicole Yeung +12 more

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

BMC Medicine(2022)10.1186/s12916-022-02298-0
N/A
0DataRank · unranked
21 citations

Hui‐Ming Lin, Edmond M. Kwan, Heidi Fettke, Ben Tran, Ian D. Davis +22 more

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

EBioMedicine(2020)10.1016/j.ebiom.2020.102728
N/A
0DataRank · unranked
136 citations

Winston Tan, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calven Wong +10 more